Focus: Dr. Reddy's Laboratories is a pharmaceutical company headquartered in Norcross, GA, specializing in small molecules and custom pharma services across neurology, oncology, cardiovascular, infectious diseases, and respiratory indications.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Dr. Reddy's Laboratories to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship product with 8+ years of patent protection; represents 19% of company revenue and anchors oncology franchise.
Help build intelligence for Dr. Reddy's Laboratories
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Dr. Reddy's Laboratories's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Generic antiarrhythmic in post-LOE phase; second-largest revenue driver but faces competitive generic pressure.
Post-LOE anti-inflammatory generic competing in crowded gout market; revenue maintenance dependent on cost leadership.
Generic immunosuppressant in post-LOE phase; targets niche but stable transplant population.
Post-LOE anticonvulsant with restricted distribution due to visual field risk; stable niche indication.
Topical antimicrobial approaching LOE; specialized indication limits market size but maintains clinical relevance.
Ultra-niche post-LOE orphan-like indication; stable but minimal revenue contribution.
Post-LOE anticoagulant competing against lower-cost alternatives; specialist indication limits growth.
Generic proton-pump inhibitor in highly competitive post-LOE market; revenue eroding under generic price compression.
209 discontinued, 302 duplicate formulations not shown
+5 more products with revenue data
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Recent layoff signals organizational restructuring; candidates should clarify role durability and department stability during interview process.
+235 more products